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Summary
The molecular identification of tumor antigens initially catalyzed substantial enthusiasm for the
development of tumor antigen-based vaccines for the treatment of cancer. However, numerous
vaccine approaches in melanoma and other cancers have yielded a low rate of clinical response,
despite frequent induction of specific T cells as detected in the peripheral blood. This observation
has prompted several investigators to begin interrogating the tumor microenvironment for biologic
correlates to tumor response versus resistance. Evidence is beginning to emerge suggesting that
distinct subsets of tumors may exist that reflect distinct categories of immune escape. Lack of
chemokine-mediated trafficking, poor innate immune cell activation, and the presence of specific
immune suppressive mechanisms can be found to characterize subsets of tumors. A non-inflamed
tumor phenotype may predict for resistance to cancer vaccines, suggesting a possible predictive
biomarker and patient enrichment strategy. But in addition, characterization of these subsets may
pave the way for catering therapeutic interventions toward the biologic features of the tumor in
individual patients.
Introduction: Molecular profiling of human melanoma metastases
The observation that clinical responses to tumor antigen-based vaccines have generally not
correlated well with biologic changes as measured in peripheral blood lymphocytes has led
to focused interrogation of tumor sites for possible predictive factors based on features of
the tumor microenvironment. One strategy for capturing a large amount of information in a
single assay has been the use of gene expression profiling of the total cellular composition of
tumors from pre-treatment biopsy material. This was first explored in our own group
through a pilot study in 19 patients vaccinated with multiple melanoma antigen peptides and
the cytokine IL-12. Supervised hierarchical clustering comparing clinical responders versus
non-responders identified a small set of genes, some upregulated and some downregulated,
in tumors from patients with a favorable clinical outcome [1]. A second melanoma vaccine
clinical trial was similarly analyzed in collaboration with Gerold Schuler's group from
Erlangen. In that dendritic cell-based immunization against class I and class II epitopes, T
cell responses were induced in the majority of patients, but no correlation between clinical
response and T cell parameters as measured in the blood was observed. In contrast, analysis
of gene expression profiling of pre-treatment tumor biopsies identified a set of immune
transcripts that clearly was associated with a favorable clinical outcome [2]. A third study
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was performed by GSK-Bio in the context of a MAGE-3 protein-based vaccine in melanoma
and non-small cell lung cancer. In that case as well, gene expression profiling of pre-
treatment tumor biopsies identified a cluster of transcripts that predicted outcome to
treatment [3]. Together, these studies support the notion that molecular profiling of the
tumor microenvironment is a candidate predictive biomarker for clinical response to these
relatively potent melanoma vaccines [4]. This hypothesis is being tested prospectively as a
scientific correlate embedded in the multi-center phase II and phase III studies of the GSK-
Bio MAGE3 vaccine in patients with melanoma.
While there is not 100% overlap of the specific genes identified in these three clinical
experiments, there is remarkable similarity in the categories of genes differentially
expressed. In tumors from favorable clinical outcome patients, transcripts encoding various
T lineage-specific markers, chemokines that can contribute to effector T cell recruitment,
and innate immune cell molecules have been observed. Perhaps paradoxically, those tumors
also appear to have the highest expression of immune inhibitory mechanisms, including
indoleamine-2,3-dioxygenase (IDO), PD-L1, and FoxP3+ regulatory T cells (Tregs). In
contrast, tumors from clinically resistant patients have shown poor expression of that gene
set and in contrast show the highest expression of angiogenesis-associated factors, indicators
of Notch and/or β-catenin pathway signaling, and serine protease inhibitors. These
observations have pointed towards specific biologic pathways that might be manipulated in
order to improve immune-mediated tumor destruction in vivo.
Barrier 1: T cell trafficking
It might be envisioned that cancer vaccines might not be effective unless activated tumor
antigen-specific T cells can successfully home to tumor sites. Trafficking of activated T
cells into target tissue sites is driven, in part, by the presence of specific chemokines which
are likely induced through local tissue inflammation. Consistent with this notion, the gene
expression profiles from pre-treatment melanoma biopsies indeed revealed expression of
chemokine transcripts in the favorable clinical outcome group. This was also associated with
the presence of T cell markers [5]. In vitro analysis of naïve versus effector CD8+ T cells
demonstrated upregulated expression of CCR1, CCR2, CCR5, and CXCR3 in the effector
stage. Based on known receptor/ligand interactions, these data suggested a potential role for
6 chemokines that might mediate attraction of CD8+ effector T cells: CCL2, CCL3, CCL4,
CCL5, CXCL9, and CXCL10. Using a transwell system in vitro, each of these chemokines
was sufficient to recruit CD8+ effector T cells, suggesting some redundancy [5]. The
MAGE-A3 vaccine trial independently confirmed high expression of CCL5, CXCL9, and
CXCL10 in favorable clinical outcome patients.
Analysis of a series of human melanoma cell lines revealed a small number of cell lines
capable of spontaneously secreting these chemokines, suggesting that at least in some cases,
differential presence of the relevant chemokines might be driven by biologic differences in
the tumor cells themselves. These chemokine-producing melanoma cells successfully
recruited activated CD8+ T cells in a reconstituted mouse xenograft setting in vivo [5].
Together, these results suggest that a subset of melanomas may have distinct properties that
allow the expression of immunologically relevant molecules such as chemokines. A major
implication of these results is that the ability of tumors to support recruitment of activated T
cells into the tumor microenvironment may influence whether a given patient develops a
clinical response following treatment with cancer vaccines. Absence of such chemokines
likely represents the major barrier to vaccine efficacy in a subset of patients.
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Barrier 2: Negative regulatiory mechanisms in the tumor microenvironment
The tumors expressing abundant chemokines also contain variable numbers of activated
CD8+ T cells. In a subset of HLA-A2+ patients from whom sufficient fresh tissue has been
available, it has been possible to show that among these T cells are those recognizing
defined melanoma antigen epitopes [6,7]. This observation raises the important question of
why those tumors are not spontaneously rejected. In fact, functional analysis of such cells
has revealed poor cytokine production and granzyme B expression upon analysis directly ex
vivo [6,8]. These results suggest that inactivation of CD8+ T cells might occur following
their recruitment into the tumor microenvironment. Multiple immune suppressive
mechanisms that may inhibit T cell function in the cancer context have been described in the
past several years [9–12]. Indeed, analysis of the melanoma metastasis gene array data
revealed that tumors which contained T cell transcripts also contained high expression of the
mRNA encoding indoleamine-2,3-dioexygenase (IDO). IDO has been shown to be involved
in the induction of peripheral immunologic tolerance in other model systems [13]. Analysis
of other candidate immune suppressive mechanisms revealed that those inflamed tumors
also contained high levels of transcripts for PD-L1 (a ligand for the inhibitory receptor on
activated T cells PD-1, [9]) and FoxP3 (a transcription factor characteristic of regulatory T
cells (Tregs), [14]). In addition, analysis for expression of the costimulatory ligands B7-1
and B7-2 revealed absence of expression in the majority of tumors, suggesting that the
melanoma microenvironment is also likely pro-anergy [15]. These results argue that a
second major category of barrier to successful immune-mediated tumor destruction is the
dominant action of at least four immune regulatory mechanisms operating within the tumor
microenvironment, thus allowing tumor escape.
Mechanistic experiments in mouse models from multiple laboratories have indicated that
each of the four negative regulatory pathways described above can be relevant for tumor
resistance to immune destruction in various models in vivo [16–20]. Interference with PD-
L1/PD-1 interactions, inhibition of IDO activity, depletion of Tregs, and reversal of T cell
anergy through exposure to homeostatic cytokines, all have been efficacious in selected
tumor models. Importantly, because multiple inhibitory mechanisms appear to operate in
concert, one may envision emergence of compensation unless two or more pathways are
blocked concurrently. Indeed, depletion of Tregs combined with homeostatic proliferation to
uncouple T cell anergy have been shown to be potently synergistic in vivo [17]. Recently,
we also have observed that PD-1 deficiency plus homeostatic proliferation also are
synergistic (unpublished data). Such combinatorial approaches will ultimately be attractive
to apply clinically.
T cell anergy is the most challenging of the above 4 immune inhibitory pathways to
successful uncouple in vivo. Currently, induction of proliferation to homeostatic cytokines,
most easily achieved through adoptive transfer into a lymphopenic recipient, is the strategy
most amenable to clinical translation [16]. However, a better understanding of the molecular
underpinnings of T cell anergy might reveal targets amenable to drug manipulation with the
goal of restoring T cell function. Recent work from our group and others has indicated that
diacylglycerol kinases (DGK), which phosphorylate diacylglycerol and deplete its
availability for activating Ras and other pathways in response to TCR/CD28 ligation, are
upregulated in anergic T cells [21,22]. Inhibition of DGKs in vitro can restore a large
proportion of cytokine production by anergic T cells. Analysis of the promoter of DGKs
followed by careful mechanistic studies have identified EGR2 as the central transcriptional
regulator for expression of DGKs and other anergy genes in the anergic state (Zheng et al.
manuscript submitted). Consistent with this notion, conditional deletion of the EGR2 gene
can render peripheral T cells resistant to anergy induction. Because of the importance of this
pathway, our group is currently screening a set of chemical libraries to phenocopy the
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EGR2-loss phenotype through pharmacologic means. It is hoped that this approach could
ultimately identify small molecule compounds that can improve T cell function in the cancer
context in vivo.
Innate immune “sensing” of tumor cells
The observation that a subset of patients with metastatic melanoma appears to be able to
prime a spontaneous anti-tumor CD8+ T cell response, all the way through the level of
homing of effector T cells into the tumor microenvironment, raised a critical new question.
Specifically, how it is possible for a tumor such as melanoma to activate the innate immune
signals necessary to trigger a productive adaptive immune response? During infection, this
frequently involves engagement of Toll-like receptors (TLRs) by conserved ligands derived
from the pathogenic organism, including bacterial wall products (such as LPS) or
hypomethylated CpG DNA sequences. Alternatively, cytosolic nucleic acid sensors trigger
innate immune activation to many viruses [23,24]. Downstream, these events trigger
activation of APCs to upregulate expression of costimulatory ligands and produce cytokines
such as IL-12. A subset of ligands can also activate the inflammasome to trigger processing
of IL-1, and also to produce innate factors such as type I IFNs [25,26]. However, it is not
immediately evident which innate immune receptor systems might be involved in the
context of “sensing” melanoma.
Interrogation of the melanoma metastasis gene expression profiling data for candidate innate
immune genes revealed that tumors having a lymphocyte signature also showed a
transcriptional profile characteristic of type I IFN signaling. Based on this observation,
mechanistic studies were performed in mice to determine whether host type I IFNs are
required for spontaneous CD8+ T cell priming in tumor models. Using a series of well-
defined transplantable tumor systems, early T cell priming in the draining lymph node can
be detected within around 1 week following tumor implantation [17]. This was preceded by
detectable production of IFN-β in the tumor-draining lymph node at around day 3. Studies
utilizing host mice deficient in either the type I IFN-α/βR or Stat1 showed defective
spontaneous T cell priming against a tumor-associated antigen, demonstrating that host type
I IFN responsiveness is necessary as an innate immune factor to bridge for priming an
adaptive immune response to tumors. Using bone marrow chimera and adoptive transfer
approaches, this defect was found to map to the level of the dendritic cell (DC)
compartment. Interrogation of DC properties revealed an isolated defect in the accumulation
of the CD8α+ DC subset within the tumor microenvironment. The necessity of CD8α+
dendritic cells for cross-priming of anti-viral CD8+ T cell responses supports a critical role
for this DC subset in vivo [27]. In fact, the Batf3 knockout mouse which has a selective
defect in CD8α+ DC development, showed an identical defect in priming CD8+ T cells to
tumor. Therefore, host type I IFN signals are required for the priming of anti-tumor CD8+ T
cells via CD8α+ dendritic cells in vivo (Fuertes and Gajewski, manuscript submitted). This
model system is similarly being utilized to identify the tumor-derived factors that induce
type I IFN production from host dendritic cells, and which receptor system is responsive to
those tumor-derived factors.
While host type I IFN production is necessary for the endogenous immune response that
arises after tumor implantation in vivo, that immune response is not sustained. T cell
dysfunction eventually develops in these models, which is associated with tumor outgrowth
[26]. This finding raised the question of whether sustained presence of type I IFNs in the
tumor site might improve tumor control. Indeed, preliminary data have indicated that
expression of either IFN-α or IFN-β by retroviral transduction can lead to total rejection of
B16 melanoma in vivo (Spaapen and Gajewski, unpublished observations). While the
mechanism of this potent therapeutic effect is being elucidated, these results already suggest
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that introduction of sustained type I IFN preparations into tumor sites is an attractive
approach to examine clinically, which might result in more potent tumor control than
systemic administration.
Hypothetical molecular differences to account for distinct tumor
microenvironments
The observation of at least two major subsets of melanoma metastases, “inflamed” and
“non-inflamed”, raises the question of what are the molecular pathways in the tumor cells
that may lead to differential expression of immune regulatory genes such as chemokines.
The vast majority of melanomas display constitutive activation of the Ras pathway, either
through mutations in N-Ras or B-Raf, or more rarely through upstream activation of growth
factor receptors. Therefore, it is unlikely that variable engagement of the Ras pathway could
explain phenotypic differences between tumors. However, several other signaling pathways
have been found to be variably activated in subsets of tumors. These include activation of
Notch signaling [28], β-catenin stabilization [29], Stat3 phosphorylation [30], PI3 kinase
[31], ErbB4 [32] and c-met [33]. Several of these pathways are candidates for
downregulating expression of immunoregulatory genes in melanoma. In vitro, knockdown
of Stat3 has direct anti-tumor activity, but also induces expression of chemokines that might
mediate lymphocyte trafficking [34]. In addition, our melanoma gene expression profiling
data have suggested a correlation between Notch pathway and/or β-catenin pathway
activation and lack of an immune infiltrate. Based on these notions, it is attractive to
evaluate the functional role of these or other signaling pathways in the melanoma cells
themselves that might regulate their ability to productively interact with the host immune
system. Such work, if successful, might lead to small molecule inhibitor approaches to alter
the tumor microenvironment from within and thus lead to improved immune-mediated
tumor control.
Conclusions: Clinical therapeutic implications
The information gleaned from gene expression profiling, combined with the preclinical
experiments dissecting mechanisms of tumor escape, have come together to suggest
therapeutic strategies to facilitate immune-mediated tumor rejection at the level of the tumor
microenvironment. For the non-inflamed tumor phenotype, it may be possible to promote
appropriate inflammatory signals to facilitate recruitment of activated T cells into the tumor
microenvironment after vaccination or adoptive T cell transfer. As proof of concept,
recombinant viral vectors could be employed to introduce selected chemokines, innate
immune factors such as IFN-β, or molecules that induce chemokines from host cells. Murine
experiments utilizing an adenoviral vector encoding LIGHT, a TNF superfamily member
that induces chemokine production from stromal cells via engagement of the LTβ receptor,
have revealed remarkable efficacy of this approach [35]. Additional non-specific
interventions that may promote desirable inflammation include introduction of TLR
agonists, such as imiquimod or CpG oligonucleotides, or administration of single fractions
of high-dose radiation [35]. These are attractive strategies to consider for clinical translation.
For the inflamed tumor phenotype, approaches for clinical application are farther along in
development. It is this subset that appears to include the clinical responders to our current
melanoma vaccine strategies. However, even by using gene expression profiling as a
predictive biomarker to enrich for patients with the inflamed phenotype, the clinical
response rate would be estimated to be around 30%. Therefore, interfering with the immune
suppressive mechanisms that appear to be dominant in the tumor microenvironment of these
patients may be the most critical therapeutic intervention strategy to consider. Early phase
clinical trials are ongoing to inhibit IDO, block PD-1/PD-L1 interactions, or deplete Tregs.
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For IDO, at least two small molecule inhibitors are being investigated. These are attractive
because of their oral bioavailability [19,36]. For the PD-1 axis, neutralizing mAbs against
either PD-1 or PD-L1 are being tested. Interestingly, results of a phase I study of the anti-
PD-1 mAb developed by Medarex and BMS were recently presented and revealed an
approximate 30% response rate in patients with melanoma, non-small cell lung cancer, and
renal cell carcinoma [37]. For Tregs, several approaches targeting CD25 are being explored.
Early data using Ontak, an IL-2/diphtheria toxin fusion protein, have shown promise
[38,39]. In addition, the anti-CD25 mAb daclizumab has been tested and appears to be able
to deplete Tregs without adversely affecting T cell priming to a vaccine [40]. A second anti-
CD25 mAb, basiliximab, is available but has not yet been investigated in this fashion for
Treg depletion and vaccine combinations.
For T cell anergy, clinically testable strategies to support reversal have been more
challenging to pursue. However, we have shown that homeostatic proliferation in a
lymphopenic recipient is one approach in preclinical models that can support recovery of
anergic T cell function and promote tumor rejection in vivo [16]. It is therefore attractive to
consider that the adoptive T cell therapy approaches that involve conditioning the patient
with lympho-depleting chemotherapy prior to adoptive transfer may be efficacious, in part,
by countering T cell anergy [41,42]. It is conceivable that this could be integrated with other
immunotherapeutic strategies, such as vaccination, Treg depletion, or blockade of PD-1 or
IDO. Another attractive approach would be through exogenous delivery of the homeostatic
cytokine IL-15 [43,44]. While clinical development of IL-15 had been stalled, the NCI has
recently manufactured a clinical grade lot of IL-15 that is entering phase I clinical trial
testing.
Ultimately, once the most effective of these new therapies have been successfully
developed, it is not difficult to envision a personalized therapy approach in the near future.
One could imagine performing an analysis of pre-treatment biopsy material to determine the
major phenotype of melanoma tumor (inflamed versus non-inflamed) through gene
expression profiling, along with an analysis of the immune suppressive pathways
dominating in the inflamed lesions. In this way, the most critical rate-limiting barriers could
be overcome through specific interventions assigned based on tissue analysis of an
individual patient's tumor. Patients with non-inflamed tumors may need to receive systemic
vaccination along with local application of inflammatory signals to promote T cell
recruitment. Patients with inflamed lesions may most critically need blockade of inhibitory
pathways, such as PD-1. Ultimately, such analyses could be integrated into the kinase
mutation analysis that currently is being utilized to select patients for agents that target B-
Raf [45] or c-kit [46].
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Two categories of tumor with distinct mechanisms of resistance to immune-mediated
destruction at the effector phase. A. The non-inflamed tumors appear to have high
expression of vascular markers as well as macrophages and fibroblasts. They have low
indicators of innate inflammation, show poor chemokine production, and have a paucity of
lymphocytes. It is hypothesized that the main reason for tumor escape in this subset is poor
effector cell trafficking. B. The inflamed tumors appear to have a rich presence of innate
immune signals, chemokines for T cell recruitment, and variable presence of T cells.
However, these tumors also contain important immune suppressive mechanisms. It is
hypothesized that the main reason for tumor escape in this subset is through dominant
effects of negative regulation.
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